Literature DB >> 34351388

Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.

Luciano Baronciani1, Ian Peake2, Reinhard Schneppenheim3, Anne Goodeve2, Minoo Ahmadinejad4,5, Zahra Badiee6, Mohammad-Reza Baghaipour7, Olga Benitez8, Imre Bodó9, Ulrich Budde10, Andrea Cairo1, Giancarlo Castaman11, Peyman Eshghi5, Jenny Goudemand12, Wolf Hassenpflug3, Hamid Hoorfar13, Mehran Karimi14, Bijan Keikhaei15, Riitta Lassila16, Frank W G Leebeek17, Maria Fernanda Lopez Fernandez18, Pier Mannuccio Mannucci1, Renato Marino19, Nikolas Nikšić2, Florian Oyen3, Cristina Santoro20, Andreas Tiede21, Gholamreza Toogeh22, Alberto Tosetto23, Marc Trossaert24, Eva M K Zetterberg25, Jeroen Eikenboom26, Augusto B Federici27, Flora Peyvandi1,28.   

Abstract

Type 3 von Willebrand disease (VWD3) is a rare and severe bleeding disorder characterized by often undetectable von Willebrand factor (VWF) plasma levels, a recessive inheritance pattern, and heterogeneous genotype. The objective of this study was to identify the VWF defects in 265 European and Iranian patients with VWD3 enrolled in 3WINTERS-IPS (Type 3 Von Willebrand International Registries Inhibitor Prospective Study). All analyses were performed in centralized laboratories. The VWF genotype was studied in 231 patients with available DNA (121 [115 families] from Europe [EU], and 110 [91 families] from Iran [IR]). Among 206 unrelated patients, 134 were homozygous (EU/IR = 57/77) and 50 were compound heterozygous (EU/IR = 43/7) for VWF variants. In 22 patients, no or only one variant was found. A total of 154 different VWF variants (EU/IR = 101/58 [5 shared]) were identified among the 379 affected alleles (EU/IR = 210/169), of which 48 (EU/IR = 18/30) were novel. The variants p.Arg1659*, p.Arg1853*, p.Arg2535*, p.Cys275Ser, and delEx1_Ex5 were found in both European and Iranian VWD3 patients. Sixty variants were identified only in a single allele (EU/IR = 50/10), whereas 18 were recurrent (≥3 patients) within 144 affected alleles. Nine large deletions and one large insertion were found. Although most variants predicted null alleles, 21% of patients carried at least 1 missense variant. VWD3 genotype was more heterogeneous in the European population than in the Iranian population, with nearly twice as many different variants. A higher number of novel variants were found in the Iranian VWD3 patients.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 34351388      PMCID: PMC8361454          DOI: 10.1182/bloodadvances.2020003397

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  81 in total

1.  Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.

Authors:  J Eikenboom; L Hilbert; A S Ribba; A Hommais; D Habart; S Messenger; A Al-Buhairan; A Guilliatt; W Lester; C Mazurier; D Meyer; E Fressinaud; U Budde; K Will; R Schneppenheim; T Obser; O Marggraf; E Eckert; G Castaman; F Rodeghiero; A B Federici; J Batlle; J Goudemand; J Ingerslev; S Lethagen; F Hill; I Peake; A Goodeve
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

2.  Improved splice site detection in Genie.

Authors:  M G Reese; F H Eeckman; D Kulp; D Haussler
Journal:  J Comput Biol       Date:  1997       Impact factor: 1.479

3.  Characterization of the mutation spectrum in a Pakistani cohort of type 3 von Willebrand disease.

Authors:  Shariq Ahmed; Hamideh Yadegari; Arshi Naz; Arijit Biswas; Ulrich Budde; Nazish Saqlain; Samina Amanat; Shehla Tariq; Fazle Raziq; Shahtaj Masood; Anna Pavlova; Tahir Sultan Shamsi; Johannes Oldenburg
Journal:  Haemophilia       Date:  2019-09-18       Impact factor: 4.287

Review 4.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

5.  von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.

Authors:  N Hickson; D Hampshire; P Winship; J Goudemand; R Schneppenheim; U Budde; G Castaman; F Rodeghiero; A B Federici; P James; I Peake; J Eikenboom; A Goodeve
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

6.  Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.

Authors:  Luciano Baronciani; Giovanna Cozzi; Maria Teresa Canciani; Flora Peyvandi; Alok Srivastava; Augusto B Federici; Pier Mannuccio Mannucci
Journal:  Blood Cells Mol Dis       Date:  2003 May-Jun       Impact factor: 3.039

7.  Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study.

Authors:  Alberto Tosetto; Zahra Badiee; Mohammad-Reza Baghaipour; Luciano Baronciani; Javier Battle; Erik Berntorp; Imre Bodó; Ulrich Budde; Giancarlo Castaman; Jeroen C J Eikenboom; Peyman Eshghi; Cosimo Ettorre; Anne Goodeve; Jenny Goudemand; Charles Richard Morris Hay; Hamid Hoorfar; Mehran Karimi; Bijan Keikhaei; Riitta Lassila; Frank W G Leebeek; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Maria Gabriella Mazzucconi; Massimo Morfini; Johannes Oldenburg; Ian Peake; Rafael Parra Lòpez; Flora Peyvandi; Reinhard Schneppenheim; Andreas Tiede; Gholamreza Toogeh; Marc Trossaert; Omidreza Zekavat; Eva M K Zetterberg; Augusto B Federici
Journal:  J Thromb Haemost       Date:  2020-08-25       Impact factor: 5.824

8.  Genetic heterogeneity in a large cohort of Indian type 3 von Willebrand disease patients.

Authors:  Priyanka Kasatkar; Shrimati Shetty; Kanjaksha Ghosh
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

9.  A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Authors:  Agnès Veyradier; Pierre Boisseau; Edith Fressinaud; Claudine Caron; Catherine Ternisien; Mathilde Giraud; Christophe Zawadzki; Marc Trossaert; Nathalie Itzhar-Baïkian; Marie Dreyfus; Roseline d'Oiron; Annie Borel-Derlon; Sophie Susen; Stéphane Bezieau; Cécile V Denis; Jenny Goudemand
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

10.  Ensembl variation resources.

Authors:  Sarah E Hunt; William McLaren; Laurent Gil; Anja Thormann; Helen Schuilenburg; Dan Sheppard; Andrew Parton; Irina M Armean; Stephen J Trevanion; Paul Flicek; Fiona Cunningham
Journal:  Database (Oxford)       Date:  2018-01-01       Impact factor: 3.451

View more
  2 in total

1.  Identification of von Willebrand factor D4 domain mutations in patients of Afro-Caribbean descent: In vitro characterization.

Authors:  Marie-Daniéla Dubois; Ivan Peyron; Olivier-Nicolas Pierre-Louis; Serge Pierre-Louis; Johalène Rabout; Pierre Boisseau; Annika de Jong; Sophie Susen; Jenny Goudemand; Rémi Neviere; Pascal Fuseau; Olivier D Christophe; Peter J Lenting; Cécile V Denis; Caterina Casari
Journal:  Res Pract Thromb Haemost       Date:  2022-06-15

2.  Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.

Authors:  Maria Teresa Pagliari; Frits R Rosendaal; Minoo Ahmadinejad; Zahra Badiee; Mohammad-Reza Baghaipour; Luciano Baronciani; Olga Benítez Hidalgo; Imre Bodó; Ulrich Budde; Giancarlo Castaman; Peyman Eshghi; Jenny Goudemand; Mehran Karimi; Bijan Keikhaei; Riitta Lassila; Frank W G Leebeek; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Renato Marino; Johannes Oldenburg; Ian Peake; Cristina Santoro; Reinhard Schneppenheim; Andreas Tiede; Gholamreza Toogeh; Alberto Tosetto; Marc Trossaert; Hamideh Yadegari; Eva M K Zetterberg; Flora Peyvandi; Augusto B Federici; Jeroen Eikenboom
Journal:  J Thromb Haemost       Date:  2022-02-22       Impact factor: 16.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.